# Eikon Therapeutics funding rounds and investors

As of 14 Oct 2026, Eikon Therapeutics has raised $350.7M across 1 verified round on record; latest: $350.7 million Series D, announced 26 Feb 2025.

Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches.

Website: https://eikontx.com  
Headquarters: HAYWARD, Calif.  
Page: https://fireround.dev/companies/eikontx.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-02-26 | Series D | $350.7 million | not stated | Alexandria Venture Investments, AME Cloud Ventures, E15 VC, Foresite Capital, General Catalyst, Lux Capital, Soros Fund Management, StepStone, The Column Group, T. Rowe Price | [eikontx.com](https://www.eikontx.com/news/eikon-therapeutics-secures-350-7-million-series-d-to-advance-clinical-stage-programs-and-future-pipeline), [fiercebiotech.com](https://www.fiercebiotech.com/biotech/eikon-remains-megaround-mode-350m-series-d-fund-cancer-trials) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.